United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings for United Therapeutics Corporation (UTHR)
Earnings in 2023 (TTM): $1.27 B
According to United Therapeutics Corporation's latest financial reports the company's current earnings (TTM) are $1.27 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of United Therapeutics Corporation
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $1.27 B | $984.8 M |
| 2022 | $950.6 M | $727.3 M |
| 2021 | $593.9 M | $475.8 M |
| 2020 | $638.9 M | $514.8 M |
| 2019 | $-165,000,000 | $-104,500,000 |
| 2018 | $758.9 M | $589.2 M |
| 2017 | $769.5 M | $417.9 M |
| 2016 | $1.06 B | $713.7 M |
| 2015 | $1.04 B | $651.64 M |
| 2014 | $525.18 M | $340.07 M |
| 2013 | $278.9 M | $174.56 M |
| 2012 | $440.67 M | $304.44 M |
| 2011 | $299.12 M | $217.87 M |
| 2010 | $147.84 M | $105.92 M |
| 2009 | $18.77 M | $19.46 M |
| 2008 | $-72,298,000 | $-42,789,000 |
| 2007 | $16.58 M | $19.86 M |
| 2006 | $39.91 M | $73.97 M |
| 2005 | $47.52 M | $65.02 M |
| 2004 | $15.45 M | $15.45 M |
| 2003 | $-9,969,000 | $-9,969,000 |
| 2002 | $-23,651,000 | $-23,651,000 |
| 2001 | $-37,287,749 | $-37,287,749 |
| 2000 | $-86,181,694 | $-75,608,490 |
| 1999 | $-35,300,000 | $-33,500,000 |
| 1998 | $-12,800,000 | $-12,800,000 |